|
[1]
|
T. Horimoto, Y. Kawaoka. Strategies for developing vaccines against H5N1 influenza A viruses. Trends in Molecular Medi- cine, 2006, 12(11): 506-514.
|
|
[2]
|
R. J. Webby, D. R. Perez, J. S. Coleman, et al. Responsiveness to a pandemic alert: Use of reverse genetics for rapid develop- ment of influenza vaccines. Lancet, 2004, 363(9415): 1099- 1103.
|
|
[3]
|
裴磊, 王国俊, 熊杰等. Clade 2.2 H5N1亚型禽流感重组灭活疫苗株的构建及其对小鼠免疫效力的评价[J]. 中国预防兽医学报, 2010, 32(9): 699-702.
|
|
[4]
|
田国彬. 禽流感疫苗的种类及使用[J]. 北方牧业, 2010, 22: 27.
|
|
[5]
|
曾显营, 钟功勋, 李雁冰等. 禽流感病毒H5N1变异株灭活疫苗(Re-4株)对鸡、鸭和鹅的免疫效果研究[J]. 中国预防兽医学报, 2010, 32(10): 800-803.
|
|
[6]
|
乔传玲, 姜永萍, 于康震等. 共表达禽流感病毒HA和NA基因的重组禽痘病毒在SPF鸡的免疫效力试验[J]. 中国农业科学, 2004, 37(4): 605-608.
|
|
[7]
|
J. Y. Ge, G. H. Deng, Z. Y. Wen, et al. New castle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. Journal of Virology, 2007, 81(1): 150-158.
|
|
[8]
|
M. Prabakaran, S. Madhan, N. Prabhu, et al. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. Journal of Virology, 2010, 84(7): 3201-3209.
|
|
[9]
|
J. A. Schwartz, L. Buonocore, A. Suguitan, Jr, et al. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. Journal of Virology, 2011, 85(9): Epub ahead of print.
|
|
[10]
|
R. J. Russell, P. S. Kerry, D. J. Stevens, et al. Structure of influ- enza hemagglutinin in complex with an inhibitor of membrane fusion. Proceedings of National Academy Sciences USA, 2008, 105(46): 17736-17741.
|
|
[11]
|
C. J. Wei, J. C. Boyington, P. M. McTamney, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science, 2010, 329(5995): 1060-1064.
|
|
[12]
|
J. Steel, A. C. Lowen, T. Wang, et al. An influenza virus vaccine based on the conserved hemagglutinin stalk domain. Mbio, 2010, 1(1): Article ID e00018.
|
|
[13]
|
A. K. Kashyap, J. Steel, A. Rubrum, et al. Protection from the 2009 H1N1 Pandemic Influenza by an antibody from combina- torial survivor-based libraries. PLoS Pathogens, 2010, 6(7): Ar- ticle ID e1000990.
|
|
[14]
|
G. Bommakanti, M. P. Citron, R. W. Hepler, et al. Design of an HA2-based Escherichia coli expressed Influenza Immunogen that Protects Mice From Pathogenic Challenge. Proceedings of National Academy Sciences USA, 2010, 107(31): 13701-13706.
|
|
[15]
|
W. Liu, P. Zou, J. Ding, et al. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes and Infection, 2005, 7(2): 171-177.
|
|
[16]
|
A. M. Eriksson, K. M. Schon and N. Y. Lycke. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intrana- sally does not cause inflammation or accumulate in the nervous tissues. The Journal of Immunology, 2004, 173(5): 3310-3319.
|
|
[17]
|
V. C. Huber, J. M. Lynch, D. J. Bucher, et al. FcR-mediated phagocytosis makes a significant contribution to clearance of in- fluenza virus infections. The Journal of Immunology, 2001, 166 (12): 7381-7388.
|
|
[18]
|
W. Fiers, M. De Filette, K. Bakkouri, et al. M2e-based universal influenza A vaccine. Vaccine. 2009, 27(45): 6280-6283.
|
|
[19]
|
姜永萍, 于康震, 邓国华等. 表达H5亚型禽流感病毒HA基因的DNA疫苗免疫保护效力研究[J]. 中国农业科学, 2004, 37(7): 1071-1075.
|
|
[20]
|
姜永萍, 张洪波, 李呈军等. HA基因密码子及表达载体优化的H5亚型禽流感DNA疫苗免疫保护效果比较[J]. 农业生物技术学报, 2006, 14(3): 301-306.
|
|
[21]
|
姜永萍, 张洪波, 张平静等. H5亚型禽流感DNA疫苗质粒pCAGGoptiHA5对商品蛋鸡的免疫保护效果[J]. 中国兽医学报, 2007, 27(1): 62-65.
|
|
[22]
|
王国俊, 熊杰, 李俊平等. H5亚型禽流感病毒A/Duck/An- hui/1/2006(Clade 2.3)密码子优化HA基因DNA疫苗的免疫保护效力研究[J]. 中国预防兽医学报, 2010, 32(2): 116-120.
|
|
[23]
|
B. Ferko, J. Stasakova, J. Romanova, et al. Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. Journal of Virology, 2004, 78(23): 13037- 13045.
|
|
[24]
|
J. Talon, M. Salvatore, R. E. O’Neill, et al. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proceedings of the National Academy of Sciences USA, 2000, 97(8): 4309-4314.
|
|
[25]
|
V. Wacheck, A. Egorov, F. Groiss, et al. A novel type of influ- enza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. Journal of Infectious Disease, 2010, 201: 354-362.
|